Skip to main content
OpenTrials

Clinical trial condition

Paraproteinemias

Explore clinical trials studying Paraproteinemias. Study availability and eligibility vary by location and protocol.

3,008 public trials 572 recruiting studies
Refine in advanced search Browse all conditions

Paraproteinemias trial results

Completed

Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

NCT02290431

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Novartis Investigative Site Nagoya, Aichi-ken, Japan
  • Novartis Investigative Site Kashiwa, Chiba, Japan
  • Novartis Investigative Site Matsuyama, Ehime, Japan
  • Novartis Investigative Site Fukuoka, Japan
View all 20 locations
View Trial Details
Completed

CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma

NCT00044018

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • H Lee Moffit Cancer Center Tampa, Florida, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Mayo Clinic Rochester, Minnesota, United States
  • St Vincent's Cancer Center New York, United States
View Trial Details
Completed

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT00065351

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Palo Verde Hematology Oncology Glendale, Arizona, United States
  • Mayo Clinic Scottsdale, Arizona, United States
  • Alta Bates Comprehensive Cancer Center Berkeley, California, United States
  • Providence St. Joseph Medical Center/Cancer Center Burbank, California, United States
View all 26 locations
View Trial Details
Completed

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

NCT01568294

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Nagoya City University Hospital Nagoya, Aichi-ken, Japan
  • Tokai University Hospital Isehara, Kanagawa, Japan
  • Saitama Medical Center, Saitama Medical University Kawagoe, Saitama, Japan
  • National Cancer Center Hospital Tyuuou, Tokyo, Japan
View Trial Details
Completed

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

NCT02348528

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Peking University Third Hospital Beijing, China
  • Peking Union Medical College Hospital Beijing, China
  • The 301 Hospital-Chinese PLA General Hospital Beijing, China
  • Xiangya Hospital of Central South University Changsha, China
View Trial Details
Completed

Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma

NCT00555100

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Nagoya City University Hospital Nagoya, Aichi-ken, Japan
  • National Hospital Organization Nagoya Medical Center Nagoya, Aichi-ken, Japan
  • Jichi Medical University Hospital Shimotsuke, Tochigi, Japan
  • Niigata Cancer Center Hospital Niigata, Japan
View Trial Details

Related conditions